The role of hypertrophy and growth factors in heart failure

Journal of Cardiac Failure
J Ross, M Hongo

Abstract

The physiologic trophic factors growth hormone (GH) and insulin-like growth factor 1 (IGF-1) generally increase body weight and cardiac mass proportionately, and several studies suggest that both growth factors cause vasodilation and increased myocardial contractility. Established clinical benefits of ACE inhibitors can be explained, at least in part, by inhibition of cell hypertrophy, lowered systemic vascular resistance (SVR) and afterload, leading to reduction of progressive left-ventricular (LV) enlargement. An alternative approach would be to administer IGF-1 or GH to stimulate compensatory hypertrophy and reduce afterload by their vasodilator action, as well as through potential favorable effects on myocardial contractility. In our initial study in the rat myocardial infarction (MI) model, when IGF-1 was administered early (at 2 days) post-MI and continued for 2 weeks, body weight (BW) increased and LV weight/BW remained unchanged, the LV end-diastolic volume (EDV) and stroke volume increased (but not when normalized to BW), and the LV ejection fraction increased in rats with large infarctions. These findings suggested a beneficial rather than detrimental effect of such treatment, and we then studied the action of combine...Continue Reading

References

Jul 1, 1975·The Journal of Clinical Investigation·W GrossmanL P McLaurin
Oct 1, 1992·Journal of Molecular and Cellular Cardiology·S R Kayar, H R Weiss
Jul 1, 1990·Physiological Reviews·V R Sara, K Hall
Jul 1, 1990·Acta Endocrinologica·E M Rutanen, F Pekonen
Nov 28, 1991·The New England Journal of Medicine·W Grossman
Dec 15, 1990·Annals of Internal Medicine·P ChansonJ Lubetzki
Dec 1, 1985·Circulation Research·J K Gwathmey, J P Morgan
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·L S MathewsR D Palmiter
Apr 1, 1985·Journal of the American College of Cardiology·J Ross
Jan 1, 1983·European Heart Journal·J Schaper, W Schaper
Dec 1, 1993·Genes & Development·L Powell-BraxtonT A Stewart
Mar 28, 1996·The New England Journal of Medicine·S FazioL Saccà

❮ Previous
Next ❯

Citations

Aug 15, 2002·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Hongkui JinNicholas F Paoni
Dec 15, 2000·Progress in Pediatric Cardiology·A M MoranJ W Newburger
Jul 30, 2005·Expert Opinion on Investigational Drugs·Catherine Demers, Robert S McKelvie
Apr 22, 2008·Journal of Molecular and Cellular Cardiology·Brian J DeBosch, Anthony J Muslin
Apr 3, 2003·Congestive Heart Failure·Catherine Demers, Robert S McKelvie
Jun 18, 2004·Annals of the New York Academy of Sciences·Michael V G LatronicoGianluigi Condorelli
Apr 24, 1999·Human & Experimental Toxicology·V GerslJ Machácková

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.